339177-26-3

Basic information

• Product Name: Panitumumab
• Synonyms: Panitumumab;Abx-egf;Abx-egf mab;Immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal abx-egf heavy chain), disulfide with human monoclonal abx-egf light chain, dimer;Unii-6A901E312a;Vectibix;Abenix
• CAS NO: 339177-26-3
• Molecular Weight: 0
• Mol File: 339177-26-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Panitumumab(CAS DataBase Reference)
• NIST Chemistry Reference: Panitumumab(339177-26-3)
• EPA Substance Registry System: Panitumumab(339177-26-3)

Safety Data

• Hazardous Substances Data: 339177-26-3(Hazardous Substances Data)

Usage

Description

Panitumumab, also known by its brand name Vectibix, is a recombinant, fully human IgG2 kappa monoclonal antibody that is highly selective for the epidermal growth factor receptor (EGFR). It is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC) with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab works by blocking the binding of ligands such as epidermal growth factor (EGF) and transforming growth factor (TGF-a) to various EGFR-expressing cell lines, which results in inhibition of EGF-dependent tumor cell activation, induction of apoptosis, and decreased pro-inflammatory cytokine and vascular growth factor production.

Uses

Used in Antineoplastic Applications:
Panitumumab is used as an antineoplastic agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma (mCRC). It is particularly effective in patients whose disease has progressed on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab's high affinity for EGFR (KD ? 50pM; IC50 ? 3 nM) in human cervical epidermal cell line A-431 makes it a promising candidate for targeted cancer therapy.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Panitumumab is used as a targeted therapy for the treatment of specific types of cancer, particularly those that overexpress the epidermal growth factor receptor (EGFR). Its high selectivity and affinity for EGFR make it a valuable tool in the development of personalized cancer treatments and contribute to the growing field of precision medicine.

Originator

Abgenix (US)

Clinical Use

Monoclonal antibody: Treatment of metastatic colorectal cancer

Drug interactions

Potentially hazardous interactions with other drugs Cytotoxics: avoid with bevacizumab, fluorouracil, irinotecan and oxaliplatin. Folinic acid: avoid concomitant use. Live vaccines: avoid concomitant use.

Metabolism

Saturable elimination mediated via reticuloendothelial system, and internalisation and degradation of EGFR.